<DOC>
	<DOCNO>NCT02375685</DOCNO>
	<brief_summary>The objective study evaluate long-term safety gevokizumab patient chronic non-infectious uveitis previously well tolerate study drug may benefit longterm treatment gevokizumab .</brief_summary>
	<brief_title>Long-term Safety Gevokizumab Treatment Patients With Chronic Non-infectious Uveitis ( EYEGUARD-X )</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>either complete participation one following : CL378989002 openlabel extension , X052130/CL378989005 doublemasked period openlabel period , X052131/CL378989006 doublemasked period openlabel period , currently benefit gevokizumab compassionate use participation gevokizumab uveitis study Male female , age ≥18 ( legal age majority country ) selection . For subject reproductive potential , willingness use highly effective contraceptive measure Meeting criterion discontinuation gevokizumab uveitis previous study . Infectious uveitis masquerade syndrome History severe allergic anaphylactic reaction study drug administration previous study gevokizumab excipient . Currently active infectious disease . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Behçet 's disease uveitis</keyword>
</DOC>